Compare iShares 7-10 Year Treasury Bond ETF (IEF) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 7-10 Year Treasury Bond ETF vs Pfizer Inc — how do they compare? iShares 7-10 Year Treasury Bond ETF trades at $93.1, while Pfizer Inc trades at $26.36 (market cap $151.73B). The key difference: Pfizer Inc pays a 6.46% dividend while iShares 7-10 Year Treasury Bond ETF pays none, and Pfizer Inc is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| IEF | PFE | |
|---|---|---|
52-Week High | $97.99 | $28.56 |
52-Week Low | $92.76 | $23.60 |
Market Cap | — | $151.73B |
Volume | — | 29,869,932 |
Sector | — | Health |
Enterprise Value | — | $203.22B |
Dividend Yield | — | 6.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEF, an ETF tracking 7-10 year US Treasury bonds, trades at $93.13, up 0.4% on the day. Technical indicators are bearish overall, with moving averages signaling sell pressure, while oscillators are neutral. Recent news highlights institutional buying interest amid rising Treasury yields and inflation concerns. The ETF pays regular dividends, with recent distributions around $0.31-$0.32 per share.
The outlook for IEF hinges on interest rate trends and inflation data. Higher yields may pressure prices, but institutional accumulation suggests long-term confidence. Key risks include Fed policy shifts and geopolitical tensions affecting oil prices and bond markets. Investors should weigh yield attractiveness against duration risk in a volatile rate environment.
Pfizer (PFE) trades at $27.05, up 1.16% with a bullish technical signal and consistent earnings beats in recent quarters. Revenue remains stable around $62-63 billion, though net income is projected to decline in 2026. The stock shows strong profitability margins and a solid balance sheet, but faces headwinds from patent expirations and competitive pressures.
The outlook is mixed: valuation multiples appear reasonable, and analyst consensus leans hold with a $27.86 target. Key risks include execution on pipeline catalysts and margin compression. Upside depends on successful drug launches and cost management amid a challenging revenue environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
